JP2021510702A - 相乗的がん治療 - Google Patents

相乗的がん治療 Download PDF

Info

Publication number
JP2021510702A
JP2021510702A JP2020538844A JP2020538844A JP2021510702A JP 2021510702 A JP2021510702 A JP 2021510702A JP 2020538844 A JP2020538844 A JP 2020538844A JP 2020538844 A JP2020538844 A JP 2020538844A JP 2021510702 A JP2021510702 A JP 2021510702A
Authority
JP
Japan
Prior art keywords
inhibitor
topoisomerase
ddr
subject
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020538844A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019140271A5 (enExample
Inventor
ダニエル ヴィー． サンティ
ダニエル ヴィー． サンティ
ショーン フォンテーヌ
ショーン フォンテーヌ
Original Assignee
プロリンクス エルエルシー
プロリンクス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロリンクス エルエルシー, プロリンクス エルエルシー filed Critical プロリンクス エルエルシー
Publication of JP2021510702A publication Critical patent/JP2021510702A/ja
Publication of JPWO2019140271A5 publication Critical patent/JPWO2019140271A5/ja
Priority to JP2023186470A priority Critical patent/JP7703001B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyethers (AREA)
JP2020538844A 2018-01-12 2019-01-11 相乗的がん治療 Pending JP2021510702A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023186470A JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862617095P 2018-01-12 2018-01-12
US62/617,095 2018-01-12
US201862674483P 2018-05-21 2018-05-21
US62/674,483 2018-05-21
US201862700147P 2018-07-18 2018-07-18
US62/700,147 2018-07-18
US201862711423P 2018-07-27 2018-07-27
US201862711421P 2018-07-27 2018-07-27
US62/711,421 2018-07-27
US62/711,423 2018-07-27
US201862716788P 2018-08-09 2018-08-09
US201862716796P 2018-08-09 2018-08-09
US62/716,796 2018-08-09
US62/716,788 2018-08-09
PCT/US2019/013314 WO2019140271A2 (en) 2018-01-12 2019-01-11 Synergistic cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023186470A Division JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Publications (2)

Publication Number Publication Date
JP2021510702A true JP2021510702A (ja) 2021-04-30
JPWO2019140271A5 JPWO2019140271A5 (enExample) 2022-01-19

Family

ID=67218383

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020538844A Pending JP2021510702A (ja) 2018-01-12 2019-01-11 相乗的がん治療
JP2020538819A Pending JP2021510701A (ja) 2018-01-12 2019-01-11 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
JP2023186470A Active JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020538819A Pending JP2021510701A (ja) 2018-01-12 2019-01-11 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
JP2023186470A Active JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Country Status (10)

Country Link
US (4) US11730836B2 (enExample)
EP (2) EP3737383A4 (enExample)
JP (3) JP2021510702A (enExample)
KR (2) KR20200110377A (enExample)
CN (2) CN111587126A (enExample)
AU (2) AU2019206623A1 (enExample)
CA (2) CA3087967A1 (enExample)
MX (3) MX2020007306A (enExample)
RU (1) RU2020126774A (enExample)
WO (2) WO2019140271A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CN114302744B (zh) 2019-07-10 2025-08-26 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
MX2022002340A (es) * 2019-08-28 2022-04-06 Prolynx Llc Inhibidores conjugados de la respuesta al daño de adn.
EP4509552A1 (en) * 2022-04-14 2025-02-19 National Institutes for Quantum Science and Technology Single-polymer particles, active molecular complex, method for producing single-polymer particles, method for measuring tumor size, method for measuring fine structure within tumor, method for imaging biological tissue, drug delivery system, and contrast agent kit
WO2024030998A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Methods of treating cancer with long-acting topoisomerase i inhibitor
WO2024031005A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Treating cancer with long-acting topoisomerase i inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528593A (ja) * 2010-05-05 2013-07-11 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
JP2013542997A (ja) * 2010-11-16 2013-11-28 アレイ バイオファーマ、インコーポレイテッド チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ
JP2016531895A (ja) * 2013-10-04 2016-10-13 プロリンクス エルエルシー Ｓｎ−３８の徐放性コンジュゲート

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256133B1 (en) 1997-01-08 2016-12-14 Sigma-Aldrich Co. LLC Bioconjugation of macromolecules
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2491661A1 (en) 2002-07-12 2004-01-22 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
AU2003280592B2 (en) 2002-10-31 2008-12-18 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
LT1675622T (lt) 2003-09-17 2017-09-11 Nektar Therapeutics Daugiašakio polimero provaistai
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
WO2008034124A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2009141826A2 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
KR20110075029A (ko) 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
WO2010059661A1 (en) 2008-11-18 2010-05-27 Baxter International Inc. Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample
CA2762877A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
AU2010321882B2 (en) 2009-11-18 2016-01-14 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
TW201215412A (en) 2010-08-30 2012-04-16 Sun Pharma Advanced Res Co Ltd Stable pharmaceutical composition
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
IN2014MN01819A (enExample) * 2012-03-05 2015-07-03 Univ Ramot
TWI486341B (zh) * 2012-05-18 2015-06-01 Univ Kaohsiung Medical 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法
WO2014194289A1 (en) 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
US20150343100A1 (en) * 2014-05-28 2015-12-03 Memorial Sloan Kettering Cancer Center Bimodal fluorophore-labeled liposomes and associated methods and systems
CN106573070A (zh) * 2014-08-13 2017-04-19 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
WO2016028636A1 (en) 2014-08-16 2016-02-25 Memorial Sloan Kettering Cancer Center Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods
JP6378584B2 (ja) 2014-08-29 2018-08-22 キヤノン株式会社 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム
US10196412B2 (en) 2014-12-24 2019-02-05 The Board Of Trustees Of The Leland Stanford Junior University Probe for imaging PARP-1 activity
EP3277681B1 (de) 2015-04-02 2019-05-08 Merck Patent GmbH Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
CA2980462C (en) * 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Nanoparticle immunoconjugates
WO2016176462A1 (en) * 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
WO2017105565A2 (en) 2015-09-10 2017-06-22 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted pet imaging and methods of their use
WO2017059397A1 (en) 2015-10-01 2017-04-06 Whitehead Institute For Biomedical Research Labeling of antibodies
US11154538B2 (en) 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
AU2017257254B2 (en) * 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
AU2017258415B2 (en) * 2016-04-29 2023-03-30 Cornell University Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
CN106084005B (zh) 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
CN107050471A (zh) * 2016-12-27 2017-08-18 中国药科大学 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528593A (ja) * 2010-05-05 2013-07-11 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
JP2013542997A (ja) * 2010-11-16 2013-11-28 アレイ バイオファーマ、インコーポレイテッド チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ
JP2016531895A (ja) * 2013-10-04 2016-10-13 プロリンクス エルエルシー Ｓｎ−３８の徐放性コンジュゲート

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. Vol.19, N0.18, JPN6022055465, 2013, pages 5003 - 5015, ISSN: 0005098645 *
EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 26, no. 12, JPN6022055467, 2017, pages 1341 - 1355, ISSN: 0005098647 *
MOLECULAR CANCER THERAPEUTICS, vol. Vol.14, No.12, Suppl.2, JPN6022055466, 2015, pages 54, ISSN: 0005098646 *
PLOS ONE, vol. 7, no. 9, JPN6022055464, 2012, pages 45248 - 1, ISSN: 0005098644 *

Also Published As

Publication number Publication date
US20230321286A1 (en) 2023-10-12
CN111587126A (zh) 2020-08-25
MX2020007442A (es) 2020-09-14
EP3737416A4 (en) 2022-03-30
EP3737416A1 (en) 2020-11-18
AU2019208024A1 (en) 2020-08-13
US20200397778A1 (en) 2020-12-24
US20240082436A1 (en) 2024-03-14
JP2021510701A (ja) 2021-04-30
RU2020126853A3 (enExample) 2022-02-14
US11730836B2 (en) 2023-08-22
KR20200109345A (ko) 2020-09-22
JP7703001B2 (ja) 2025-07-04
MX2020007306A (es) 2020-09-25
CA3087967A1 (en) 2019-07-18
WO2019140266A1 (en) 2019-07-18
JP2024012442A (ja) 2024-01-30
WO2019140271A2 (en) 2019-07-18
RU2020126774A (ru) 2022-02-14
EP3737383A2 (en) 2020-11-18
KR20200110377A (ko) 2020-09-23
CN111587115A (zh) 2020-08-25
MX2023005786A (es) 2023-05-29
EP3737383A4 (en) 2021-12-15
US20200360545A1 (en) 2020-11-19
WO2019140271A3 (en) 2019-08-22
RU2020126853A (ru) 2022-02-14
CA3087628A1 (en) 2019-07-18
AU2019206623A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
JP7703001B2 (ja) 相乗的がん治療
RU2760185C2 (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
Hingorani et al. Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
ES2834927T3 (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
JP6949859B2 (ja) Ｄｂａｉｔ分子の全身投与によるガンの処置
EA023927B1 (ru) ОПТИМИЗИРОВАННАЯ С ПОМОЩЬЮ ЭНДОСОМОЛИТИЧЕСКИХ СРЕДСТВ СИСТЕМА ДОСТАВКИ in vivo КОНЪЮГАТОВ НУКЛЕИНОВОЙ КИСЛОТЫ
JP2018507249A (ja) Ｒａｓ変異と関連するがんの治療方法
TW202216209A (zh) 抗體-藥物結合物及atm抑制劑之組合
EA023793B1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
JP7772847B2 (ja) 抗がん剤の送達のためのステレオコンプレックス
Huang et al. Chiral coordination polymer nanowires boost radiation-induced in situ tumor vaccination
TW202329936A (zh) 抗體-藥物結合物與parp1選擇性抑制劑之組合
RU2786675C2 (ru) Синергическое лечение рака
WO2020228656A1 (zh) 用于联合治疗软组织肉瘤的喹啉衍生物
US20250186438A1 (en) Treatment of clear cell renal cell carcinoma
CN110381952B (zh) 作为治疗剂用于治疗骨癌或血癌的磷铂化合物
JP2023501433A (ja) 異種組織細胞組成物の使用方法
WO2025181652A1 (en) Treatment of cancer using aripiprazole and anticancer agent
JPWO2020117742A5 (enExample)
RADOSAVLJEVI Best of ASCO 2005 in clinical research for lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200915

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200714

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210326

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704